Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cardiotoxicity of Cancer Therapy (CCT)
Sponsor: Abramson Cancer Center at Penn Medicine
Summary
The objective of this study is to define the clinical significance of mechanistic biomarkers (including Neuregulin-1Beta) and novel echocardiographic measures of cardiac function in predicting the incident risk of cancer therapy cardiotoxicity.
Official title: Cardiotoxicity of Cancer Therapy: Mechanisms and Predictors
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
700
Start Date
2010-07
Completion Date
2037-04
Last Updated
2026-02-09
Healthy Volunteers
No
Conditions
Interventions
Echocardiography
Prior to chemotherapy, prior to and after anthracyclines, every 6 weeks during trastuzumab, and yearly for up to 10 years.
Blood Collection
Drawn at first chemo treatment and periodically during treatment (exact schedule varies with clinically ordered treatment plan), then annually for up to 10 years. Blood is banked for future biomarker testing.
Symptoms Questionnaire
Survey collected at first chemotherapy, periodically during therapy (exact schedule determined by clinically ordered treatment regimen), and annually for up to 10 years.
Locations (1)
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States